Navamedic ASA

LSE:0FDB Stock Report

Market Cap: NOK 448.6m

Navamedic Valuation

Is 0FDB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0FDB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0FDB (NOK28) is trading below our estimate of fair value (NOK133.08)

Significantly Below Fair Value: 0FDB is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0FDB?

Key metric: As 0FDB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0FDB. This is calculated by dividing 0FDB's market cap by their current earnings.
What is 0FDB's PE Ratio?
PE Ratio22.9x
EarningsNOK 19.62m
Market CapNOK 448.63m

Price to Earnings Ratio vs Peers

How does 0FDB's PE Ratio compare to its peers?

The above table shows the PE ratio for 0FDB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31.8x
EAH ECO Animal Health Group
73.1x39.2%UK£48.1m
ANCR Animalcare Group
32x5.3%UK£147.3m
HIK Hikma Pharmaceuticals
19.2x11.0%UK£4.5b
C4XD C4X Discovery Holdings
2.9x-88.3%UK£30.3m
0FDB Navamedic
22.9x29.6%NOK 448.6m

Price-To-Earnings vs Peers: 0FDB is good value based on its Price-To-Earnings Ratio (22.9x) compared to the peer average (31.8x).

Price to Earnings Ratio vs Industry

How does 0FDB's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0FDB 22.9xIndustry Avg. 19.7xNo. of Companies11PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0FDB is expensive based on its Price-To-Earnings Ratio (22.9x) compared to the European Pharmaceuticals industry average (19.7x).

Price to Earnings Ratio vs Fair Ratio

What is 0FDB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0FDB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 0FDB's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0FDB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
NOK 37.00
0%
2.7%NOK 38.00NOK 36.00n/a2
Dec ’25NOK 25.20
NOK 37.00
+46.8%
2.7%NOK 38.00NOK 36.00n/a2
Nov ’25n/a
NOK 45.50
0%
1.1%NOK 46.00NOK 45.00n/a2
Oct ’25n/a
NOK 45.50
0%
1.1%NOK 46.00NOK 45.00n/a2
Sep ’25n/a
NOK 45.50
0%
1.1%NOK 46.00NOK 45.00n/a2
Aug ’25n/a
NOK 46.50
0%
1.1%NOK 47.00NOK 46.00n/a2
Jul ’25n/a
NOK 46.50
0%
1.1%NOK 47.00NOK 46.00n/a2
Jun ’25n/a
NOK 49.00
0%
6.1%NOK 52.00NOK 46.00n/a2
May ’25n/a
NOK 49.00
0%
6.1%NOK 52.00NOK 46.00n/a2
Apr ’25n/a
NOK 51.00
0%
2.0%NOK 52.00NOK 50.00n/a2
Mar ’25n/a
NOK 49.00
0%
2.0%NOK 50.00NOK 48.00n/a2
Feb ’25n/a
NOK 49.00
0%
2.0%NOK 50.00NOK 48.00n/a2
Jan ’25n/a
NOK 49.00
0%
2.0%NOK 50.00NOK 48.00n/a2
Dec ’24n/a
NOK 49.00
0%
2.0%NOK 50.00NOK 48.00NOK 25.202
Nov ’24n/a
NOK 47.00
0%
6.4%NOK 50.00NOK 44.00n/a2
Oct ’24NOK 39.30
NOK 47.00
+19.6%
6.4%NOK 50.00NOK 44.00n/a2
Sep ’24n/a
NOK 47.00
0%
6.4%NOK 50.00NOK 44.00n/a2
Aug ’24n/a
NOK 50.50
0%
5.0%NOK 53.00NOK 48.00n/a2
Jul ’24n/a
NOK 49.00
0%
8.2%NOK 53.00NOK 45.00n/a2
Jun ’24n/a
NOK 49.00
0%
8.2%NOK 53.00NOK 45.00n/a2
May ’24n/a
NOK 50.00
0%
10.0%NOK 55.00NOK 45.00n/a2
Apr ’24n/a
NOK 50.00
0%
10.0%NOK 55.00NOK 45.00n/a2
Mar ’24n/a
NOK 50.00
0%
10.0%NOK 55.00NOK 45.00n/a2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 18:11
End of Day Share Price 2024/12/16 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Navamedic ASA is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Espen JørgensenDNB Markets
Gediminas RuginisNorne Securities AS
Juste SubataviciuteNorne Securities AS